Introduction
============

Around 3%--8% of all global deaths and 4% of global disability-adjusted life years can be attributed to alcohol.[@b1-ndt-10-1025] Although the first step in the treatment of alcohol dependence (detoxification) is straightforward, the major problem faced by clinicians concerns the prevention of relapse. Between 40% and 70% of patients who undergo psychosocial therapies typically resume alcohol use within 1 year of treatment.[@b2-ndt-10-1025] Relapse is more likely to occur in the 3 months following the end of detoxification.[@b3-ndt-10-1025] Clinically, it is critical to identify mechanisms that can predict relapse to optimize postdetoxification treatments.[@b4-ndt-10-1025]

Impaired inhibitory control is known to be a main variable that triggers relapse in alcohol-dependent individuals. Impairment of response inhibition (RI), the motor-behavior dimension of inhibitory control, defined as the inhibition of a preplanned motor response,[@b5-ndt-10-1025] makes it difficult for an individual to stop using alcohol and promotes the continuation of drinking.[@b6-ndt-10-1025] Assessing neural correlates of RI is useful, because RI is supported by the right prefrontal cortex in healthy individuals, a region known to be preferentially affected by alcohol ingestion.[@b7-ndt-10-1025] A common way to explore the neural processes underlying RI is the recording of event-related potentials (ERPs) during a "go/no-go" task. The task requires subjects to respond to frequent "go" trials, and to refrain from responding to rare "no-go" stimuli. This elicits two ERP components: the no-go N2, thought to reflect conflict monitoring,[@b8-ndt-10-1025] and the no-go P3, known to index the inhibition function.[@b9-ndt-10-1025] The "difference" wave (P3d) is calculated by subtracting go P3 from no-go P3, and is thought to express the "inhibitory" go/no-go effect.[@b10-ndt-10-1025],[@b11-ndt-10-1025] Previous findings suggest that no-go N2 seems to be unaffected by excessive alcohol intake,[@b12-ndt-10-1025]--[@b14-ndt-10-1025] while effects on no-go P3 are more pronounced. Two types of abnormalities of inhibition-related neural substrates have been underlined in the alcohol-abuse field. On the one hand, a lack of inhibitory skills has been associated with decreased neural activation (indexed by decreased no-go P3 amplitudes) in alcohol abusers and their relatives compared with those of controls.[@b13-ndt-10-1025],[@b15-ndt-10-1025] On the other hand, successful inhibition responses in heavy drinkers have been linked to increased inhibition-related neural activity (indexed by increased no-go P3 amplitudes and higher prefrontal cortex activation) compared with controls, which reflect compensatory neurofunctional mechanisms allowing drinkers to achieve performance levels similar to those in controls.[@b16-ndt-10-1025],[@b17-ndt-10-1025] Recent studies have shown that electrophysiological recovery of inhibitory-control processes in drug abusers is a function of abstinence,[@b18-ndt-10-1025],[@b19-ndt-10-1025] strengthening the notion that disinhibition is a key process for maintaining alcohol addiction.[@b20-ndt-10-1025]

Apart from RI impairment, alcohol-cue reactivity has also been suggested as a mechanism underlying the maintenance of alcohol dependence.[@b21-ndt-10-1025] Repeated alcohol consumption leads to alterations in dopamine levels and mesocorticolimbic sensitization, resulting in heightened incentive salience of stimuli associated with drinking.[@b22-ndt-10-1025] Contact with these attention-grabbing cues could guide patients to resume alcohol consumption after several years of abstinence.[@b23-ndt-10-1025] Accordingly, a few studies indicate that alcohol-cue reactivity is associated with relapse risk.[@b4-ndt-10-1025],[@b24-ndt-10-1025]--[@b26-ndt-10-1025]

Both cognitive mechanisms of behavioral control and alcohol-cue reactivity have long been investigated separately. However, numerous theories suggest that they interact with each other and act together to induce unreasonable consumption levels and reconsumption after abstinence.[@b22-ndt-10-1025],[@b23-ndt-10-1025],[@b27-ndt-10-1025] It is hypothesized that attention directed toward alcohol-related stimuli heightens the urge to drink, while impaired control mechanisms make it more difficult for alcoholics to resist these urges to consume alcohol.[@b24-ndt-10-1025] Therefore, alcohol consumption continues, despite well-known deleterious alcohol consumption-related consequences.[@b28-ndt-10-1025] To date, while this interaction has been demonstrated in heavy drinkers typically exhibiting more commission errors and differential brain activity in the presence of alcohol stimulations compared to light drinkers,[@b14-ndt-10-1025],[@b29-ndt-10-1025]--[@b32-ndt-10-1025] evidence supporting decreased inhibitory skills while confronted with alcohol-related stimuli are mixed in alcohol-dependent patients,[@b33-ndt-10-1025],[@b34-ndt-10-1025] and data have not been linked with treatment outcomes. Evidence of the existence in relapsers (Rs) of these pathological cognitive features and their suggested interaction would have potential clinical impact, as it has been shown that training RI alters the evaluation of stimuli associated with a stopping response, and increases inhibitory control over these stimuli in heavy drinkers.[@b35-ndt-10-1025]

We aimed to develop a technique for screening recently detoxified alcoholics to determine an individual's risk of relapse. To achieve this, we used a variant of the go/no-go task,[@b14-ndt-10-1025] with long-lasting alcohol-related contexts or not (neutral, nonalcohol-related background), performed during an ERP recording known to be highly sensitive to even minor cognitive restrictions.[@b36-ndt-10-1025] We hypothesized that: 1) because of the imbalance between RI and alcohol-cue reactivity, patients would have a higher rate of commission errors than controls, particularly in the alcohol-related context; and 2) as patients would perform the inhibition task with greater difficulty than controls, correct inhibition responses would modulate the no-go P3 or the P3d component amplitudes compared to matched controls, while no-go N2 would be spared.[@b12-ndt-10-1025]--[@b14-ndt-10-1025]

Materials and methods
=====================

Participants
------------

Inpatients diagnosed with alcohol dependence according to *Diagnostic and Statistical Manual of Mental Disorders* (DSM)-IV criteria were recruited as volunteers during the third week of their treatment from the Alcohol Detoxification Program of the Institute of Psychiatry, Brugmann Hospital (Brussels, Belgium). Healthy controls sex- and age-matched to alcohol-dependent patients were also recruited. Healthy individuals whose alcohol consumption exceeded 14 standard drinks/week (seven for women) or four drinks/day (three for women) were excluded because their consumption pattern placed them at risk for alcohol-related problems, according to the National Institute on Alcohol Abuse and Alcoholism.[@b37-ndt-10-1025] Exclusion criteria for both groups included current DSM-IV[@b38-ndt-10-1025] diagnosis of axis I disorders (other than alcohol dependence for patients) and of axis II, significant previous or current medical problems, visual impairment, head injury affecting the central nervous system, and current medical treatment that could interfere with and/or reduce the cognitive ability to perform the task. In our study, patients (n=27, seven females) were 20--68 years old, and controls (n=27, seven females) were 24--72 years old. Control participants abstained from alcohol consumption for at least 24 hours before testing. Participants in the patient group were tested prior to discharge, approximately 3 weeks after admission. The local ethics committee at Brugmann Hospital approved our study. Informed written consent was obtained from each participant.

Go/no-go task
-------------

We used the go/no-go task we previously developed[@b14-ndt-10-1025] to assess the modulation of inhibition by alcohol-related context. During the go/no-go task, participants were instructed to press a button with the thumb of their right hand, as fast and accurately as possible, whenever the letter M (go) was displayed, and to withhold pressing the button when the letter W (no-go) was displayed. Both letters were superimposed on pictorial backgrounds denoting three different emotional contexts. The neutral background (NC) was represented by a black screen, while two different alcohol-related pictures represented the alcohol background (AC), and two different nonalcohol-related pictures the nonalcohol background (NAC) (see [Figure 1](#f1-ndt-10-1025){ref-type="fig"}). The neutral background was displayed twice, and the order of all context presentation was counterbalanced across participants. Overall, the task comprised six separate stimulation blocks. In order to establish an ongoing response to be inhibited, each block contained 133 letters, divided into 93 go (70%) and 40 no-go (30%) letters. Go and no-go letters were displayed in a semirandom order to avoid the consecutive presentation of two no-go letters within each block. One to four go letters could precede no-go letters. Each task consisted of the presentation of a background screen (black for NC, or AC or NAC; 500 ms), then the letter M or W appeared on this background screen for 200 ms, followed by a return to the initial background screen (1,300 ms). Therefore, subjects had a maximum of 1,500 ms to press the button before the next letter appeared. Participants were asked to look at the center of the screen continuously and to refrain from moving and blinking during blocks to reduce interference caused by movements.

Procedure
---------

Participants were instructed to rate their urge to drink alcohol at the commencement of the study using a 100 mm visual analog scale.[@b39-ndt-10-1025] Next, participants sat in a darkened room on a chair approximately 1 m from a computer screen. The go/no-go task was administered after a practice block. Following the task, participants were asked to assess their craving scale and complete the following questionnaires: the Alcohol Use Disorder Identification Test (AUDIT[@b40-ndt-10-1025]); the UPPS (urgency \[lack of\], premeditation, perseverance \[lack of\], sensation seeking) impulsive behavior scale,[@b41-ndt-10-1025] a measure of impulsivity as a personality trait; the State-Trait Anxiety Inventory (STAI[@b42-ndt-10-1025]); the Beck Depression Inventory (BDI[@b43-ndt-10-1025]); and a questionnaire about alcohol and other drug consumption (history, characteristics, and degree of family history of alcoholism \[FHA\], if any).

Relapse evaluation
------------------

For alcohol-dependent individuals, a 3-month follow-up was conducted to gather information about drinking behavior once the detoxification program had ceased. Relapse was defined as the reinstallation of a state of alcohol dependence according to DSM-IV criteria, and treated as a binary outcome variable.[@b44-ndt-10-1025],[@b45-ndt-10-1025] According to Wiers et al[@b44-ndt-10-1025] unique reconsumption that did not exceed 3 days and after which the patient recovered control without further negative consequences was not defined as proper relapse. Information was obtained by telephone, and supplied directly by patients, family members, or the patient's regular doctor.

Electroencephalography recordings
---------------------------------

Electric brain potentials were recorded during the go/no-go task using 32 electrodes mounted on a Quik-Cap (ANT^®^ Neuro, Eenschede, the Netherlands) and placed in a standard 10--20 system at intermediate positions. A common physically linked mastoid reference was used; data were later re-referenced to the average value for this common reference.[@b46-ndt-10-1025] Battery-operated amplifiers with a gain of 30,000 and a band pass of 0.01--100 Hz (ANT Neuro, Enschede, the Netherlands) were used. The impedance of all electrodes was kept under 10 kV, with the ground electrode (AFz) positioned between the frontoparietal zero electrode (Fpz) and frontal zero electrode (Fz) along the midline. Electroencephalography was recorded continuously at a sampling rate of 1,024 Hz with eeprobe™ software (ANT^®^ Neuro, Eenschede, the Netherlands). Trials disrupted by eye movements or muscular artifacts were manually eliminated offline using the procedure developed by Semlitsch et al.[@b47-ndt-10-1025] Epochs were created from -200 ms to 800 ms after the onset of stimuli (−200 to 0 was considered the prestimulus baseline). Data were filtered with a 30 Hz low-pass filter.

Data collection
---------------

Three stimulus aspects were recorded: trial type (go or no-go); context (NC, AC, or NAC); and the response (key press for go stimuli, no key press for no-go stimuli). For each participant and context, average ERP waves were separately calculated at sites for go and no-go tasks. Incorrect responses (miss for go, or false alarm for no-go) were excluded from electroencephalography analyses. The maximum peak amplitudes of the go and no-go N2 along with the go and no-go P3 components were recorded. The no-go N2 was defined as the greatest negative value within the 200--300 ms interval after stimulus onset, and was studied in a cluster of frontoparietocentral electrodes (FC1, FC2, Cz, CP1, CP2, and Pz).[@b48-ndt-10-1025]--[@b50-ndt-10-1025] The no-go P3 was defined as the greatest positive value within the 300--500 ms interval after stimulus onset, and was studied at the same cluster of electrodes.[@b48-ndt-10-1025]--[@b50-ndt-10-1025] To highlight the specific inhibitory no-go effect, difference waveforms were calculated by subtracting the average go waveform from the average no-go waveform (no-go -- go waveform).[@b11-ndt-10-1025],[@b49-ndt-10-1025]--[@b51-ndt-10-1025]

Statistical analysis
--------------------

We analyzed ERP and behavioral data using analysis of covariance (ANCOVA). Simple effects were explored, and interaction sources were systematically examined. Student's *t*-tests and Bonferroni post hoc *t*-tests were used where appropriate. Logistic regression analyses were used to examine predictors of relapse within the follow-up period. All analyses were conducted with SPSS 17.02 (SPSS, Chicago, IL, USA), with the level of significance at 0.05.

Results
=======

Demographic and clinical variables
----------------------------------

We summarized the characteristics of all patients and controls in this study ([Table 1](#t1-ndt-10-1025){ref-type="table"}). Patients reported higher degrees of impulsivity (ie, UPPS score) and FHA than controls. It is known that compared to individuals without FHA, individuals with FHA are more impulsive[@b52-ndt-10-1025] and show differential brain responses to stimuli associated with alcohol.[@b53-ndt-10-1025] So as not to confound the roles of the variables studied, we included the degree of FHA as a covariate in subsequent analyses of the inhibition task, along with impulsivity level.

Inhibition task
---------------

The results of the go/no-go task will be presented in the form of questions related to the hypotheses presented in the Introduction section.

### Do patients and controls differ in their performance in the go/no-go task?

We compared the inhibitory capacities of the patient and control groups for our modified go/no-go task. Behavioral outcomes of performance on the inhibition task included omission-error rates (no response in go trials), commission-error rates (key press in no-go trials), and reaction times (RTs) to go stimuli. Omission and commission errors were divided by the number of trials and converted into percentages. We conducted ANCOVAs separately on error rates and RTs using the patient and control groups as the between-subject factor. The two within-subject factors of interest were trial type (go versus no-go) and context (AC versus NAC versus NC). That is, a trial type × context × group ANCOVA with FHA and UPPS as covariates was used to analyze behavioral accuracy during the go/no-go task and a context × group ANCOVA with FHA and UPPS as covariates was used to analyze RTs in go trials (see [Table 2](#t2-ndt-10-1025){ref-type="table"}).

According to error rates, a main effect of the trial type was observed (*F*~1,50~=5.775, *P*=0.020; *η*^2^=0.104, observed power =0.654), showing that all participants were less accurate in no-go than go trials (17.2% versus 1.11%, respectively). There was also an effect for group (*F*~1,50~=16.834, *P*\<0.001; *η*^2^=0.252, observed power =0.980), which indicated that overall task performance was less accurate in patients than in controls (error rates were 13.2% and 5.1%, respectively), independent of context. Finally, a significant trial type × group effect was found (*F*~1,53~=13.437, *P*=0.001; *η*^2^=0.212, observed power =0.949). To clarify this interaction, we performed two separate ANCOVAs for go and no-go accuracy scores. Analysis of go trials showed a main effect for group, indicating that patients made more omission errors than controls (*F*~1,50~=9.546, *P*=0.003; *η*^2^=0.160, observed power =0.858). Analysis of no-go trials showed a robust group effect, suggesting that patients also made more commission errors than controls (*F*~1,50~=15.501, *P*\<0.001; *η*^2^=0.237, observed power =0.971). However, differences between patients and controls were more pronounced in no-go trials: the difference in error rates for no-go trials between patients and controls was significantly higher than that for go trials in both groups (11.48% versus 1.07%, *t*~26~=−4.248; *P*\<0.001). No significant effect was observed for RTs in conjunction with any of the variables studied (*P*\>0.293). Effects due to context, UPPS, and FHA were not observed in our analyses.

### What is the neurophysiological counterpart of this behavioral difference?

To investigate whether poor inhibition capacity observed in patients was associated with abnormal electrophysiological activity, we conducted ANCOVAs similar to those for error rates, with an additional six-level within-subject factor, ie, electrode (FC1, FC2, Cz, CP1, CP2, Pz), on the classical electrophysiological correlates of the go/no-go task, N2 and P3 components.[@b49-ndt-10-1025]

For P3 amplitudes, we observed a main effect of trial type (*F*~1,50~=8.97, *P*=0.004; *η*^2^=0.152, observed power =0.836), and a trial type × group interaction (*F*~1,50~=4.741, *P*=0.034; *η*^2^=0.087, observed power =0.570). In all participants, the more difficult (less accurately performed) inhibition-response process assessed in no-go trials was associated with higher no-go P3 peaks (mean 13.29 μV) compared to the easier activation-response process, linked to lower go P3 peaks (mean 9.60 μV). By collapsing data from contexts and electrodes, paired *t*-tests were secondly used in order to untangle the interaction. The patient and control groups did not differ with respect to amplitudes in go trials (*P*=0.877); however, the patient group demonstrated higher amplitudes in no-go trials compared with controls (*t*~26~=2.309, *P*=0.026). On this basis, in order to isolate the inhibition go/no-go process per se, referred to as P3d,[@b11-ndt-10-1025],[@b50-ndt-10-1025],[@b51-ndt-10-1025],[@b54-ndt-10-1025] we finally performed an analysis on NoGo minus Go waveform, in order to verify whether a group effect specifically affecting P3d was also observable. This showed a group effect indicating that the P3d was larger in patients compared to controls (*F*~1,50~=4.762, *P*=0.034; *η*^2^=0.087, observed power =0.572). In other words, we observed equal go P3 amplitudes between groups, combined with increased no-go P3 amplitudes in patients compared to controls, giving rise to a statistically different P3d waveform. Original go/no-go P3 and P3d waves are represented in [Figure 2](#f2-ndt-10-1025){ref-type="fig"}. Analysis of N2 amplitudes did not reveal any significant effects that could be attributed to any of the variables studied (*P*\>0.140).

### Can we distinguish relapsers from nonrelapsers on the basis of response inhibition?

In this study, an RI deficit was assessed between patients and controls at two levels: behavioral and neurophysiological. Therefore, we wondered respectively whether patients who reported relapse to drinking within the 3-month follow-up period, ie, the Rs, would perform worse than patients who did not relapse, ie, the nonrelapsers (NRs), and whether the mean P3d amplitude would be even more important in Rs compared to NRs.

Within the 3-month follow-up period, 48% (13 of 27) of patients relapsed. Of the 27 patients, six reported consuming one or more sips of alcohol without losing control and without dropping back into a state of dependence. These six patients were then included in the group of NRs (n=14). The clinical and demographic characteristics of Rs and NRs are summarized in [Table 3](#t3-ndt-10-1025){ref-type="table"}. Apart from age, variables were consistent between the two groups. ANCOVA analyses were thus systematically reconducted with age as an additional covariate, in order to check for a possible influence of age on the results.

We first computed a trial × context × group ANCOVA on error rates and RTs with age, FHA, and UPPS as covariates (see [Table 4](#t4-ndt-10-1025){ref-type="table"}). The results were negative, as no significant group effects were observed for either error rates (*P*=0.313) or RTs (*P*=0.530). Secondly, we conducted similar ANCOVAs on the P3d component, as this difference wave indexed the inhibition go/no-go deficit per se in patients. The context × group (Rs versus NRs) ANCOVA on P3d showed a group effect indicating that the P3d was larger in Rs compared to NRs (*F*~1,23~=5.673, *P*=0.026; *η*^2^=0.198, observed power =0.626). Accordingly, an ANCOVA on P3d amplitudes with a three-level group variable (control, R, NR) revealed that the Rs' P3d amplitudes were significantly higher than those of the controls (*P*=0.012) whereas the NRs' P3d amplitudes were not (*P*=0.1). P3d waves of the three groups are represented in [Figure 3](#f3-ndt-10-1025){ref-type="fig"}. Individually, ten of the 13 Rs showed mean P3d amplitudes that were higher than those of controls (2.9 μV). Effects due to context and other covariates (UPPS, FHA, and age) were not found in these analyses.

Finally, logistic regression analyses were performed to ascertain to what extent electrophysiological substrates of RI (the P3d) predicted relapse and time to relapse to drinking within the 3-month follow-up. First, logistic regression revealed that P3d amplitude was the only variable that independently and significantly predicted the odds of relapse. This latter increased by a factor of 1.62 for each additional microvolt in the P3d amplitude. [Table 5](#t5-ndt-10-1025){ref-type="table"} depicts the logistic regression results.

Secondly, the Cox regression model with a backward Wald stepwise elimination procedure for time to relapse using the same covariates as in the multiple regression analysis showed that P3d amplitude and the UPPS score constituted the best predictors of relapse, as they significantly predicted the timing of relapse. Patients with higher UPPS score and/or greater P3d amplitude were respectively 1.032 and/or 1.220 times more likely to relapse, and relapse sooner, than those with lower UPPS score and P3d amplitude. [Table 6](#t6-ndt-10-1025){ref-type="table"} depicts the Cox regression results.

Discussion
==========

In our work reported here, we confirmed that when confronted with a go/no-go task, recently detoxified alcoholic patients committed more commission errors than matched controls. However, this was independent of the context. Alcohol-related contexts did not increase the error rate in patients. This previously described observation[@b55-ndt-10-1025],[@b56-ndt-10-1025] corresponds with recent data suggesting that alcohol-cue reactivity might be reduced[@b57-ndt-10-1025] or even inverted[@b25-ndt-10-1025],[@b45-ndt-10-1025],[@b58-ndt-10-1025]--[@b60-ndt-10-1025] through detoxification; therefore, its impacts upon inhibitory skills could be decreased. The reduction of alcohol-cue reactivity has been explained as the result of an active avoidance strategy of alcohol cues deployed in patients trying to remain abstinent and aware of the negative consequences of alcohol, rendering it undesirable.[@b58-ndt-10-1025] Overt, unrestrained bias toward alcohol-related stimuli[@b58-ndt-10-1025],[@b60-ndt-10-1025],[@b61-ndt-10-1025] and influence of alcohol cues on inhibition[@b62-ndt-10-1025]--[@b64-ndt-10-1025] observed to the contrary in heavy and social drinkers would be explained by the fact that alcohol is not seen as a problem in this population, and no avoiding strategies are meant to be set up.

Our major aim was to complement findings on inhibitory neural processes with neural correlates obtained through ERPs, and to assess whether these could predict relapse during a 3-month follow-up period. When they correctly inhibited a response, patients required more neural resources than controls, as shown by increased P3d. Increases in P3 amplitude are commonly interpreted as indicators that increased cognitive resources are being recruited for inhibition.[@b11-ndt-10-1025],[@b16-ndt-10-1025],[@b48-ndt-10-1025],[@b50-ndt-10-1025],[@b65-ndt-10-1025],[@b66-ndt-10-1025] The larger P3d amplitude in patients may hence attest to the need for additional neural resources recruitment required to perform the task correctly. Kamarajan et al[@b13-ndt-10-1025] noted that alcoholics exhibited significantly lower P3 amplitudes under no-go and go conditions, implying deficient processing of both RI and activation. This divergence could be attributed to the clinical severity of alcohol dependence, to task differences, and/or to a positive effect of detoxification. Further research is required to assess inhibitory skills in alcohol-dependent patients.

Though evidence of a relationship between measures of impulsive action or choice and the propensity to relapse have been accumulating with regard to tobacco-smoking dependence,[@b67-ndt-10-1025]--[@b73-ndt-10-1025] few previous studies have revealed indices of inhibitory control to be predictive of relapse in alcohol dependence. A pilot study by Bowden-Jones et al[@b74-ndt-10-1025] showed that recently detoxified alcoholics were more likely to relapse within 3 months if they scored higher in a behavioral task of impulsive choice. Evren et al[@b75-ndt-10-1025] found that impulsivity traits appeared to be somewhat related with craving and relapse. Any link so far has remained mainly speculative with respect to alcohol dependence, impulsive patients, and treatment outcomes.

In this study, we established a link between P3d increase in patients and relapse. A comparison of Rs and NRs revealed that both groups had similar error rates. The P3d generated by Rs was significantly higher than that produced by NRs. Predicted Rs needed to activate more cognitive resources during the inhibition process to perform RIs. P3d amplitude significantly predicted relapse above all other factors, with level of impulsivity and P3d magnitude predictive of time to relapse.

Our study results are preliminary, given the small number of subjects included and the resulting low power in our results, as well as the short time frame of the follow-up period. Besides RI, error processing represents another important dimension of impulsivity.[@b76-ndt-10-1025] It has also been found to be compromised in impulsive populations and in addictive pathologies in particular, as indexed by reduced error-related negativity and/or error-positivity amplitude.[@b76-ndt-10-1025]--[@b79-ndt-10-1025] These components thus certainly deserve to be investigated in further studies focusing on inhibition in relapse prediction. Analysis of failed inhibition trials will also help us to confirm our present hypothesis of enhanced P3d amplitudes as the reflection of an increased recruitment of resources to perform inhibition. Provided that attention, focus and motivation are correlated with good completion of the task, increased P3d in successful trials would suggest that an enhanced P3d amplitude indexes a necessity of increased resources being recruited as compared to healthy controls. Therefore, for instance when the task is more complex, too many resources will be needed in relapsing patients, and will prevent them from accurately performing the task. To this aim, the use of paradigms enabling the observation of a more significant amount of errors (high enough to permit ERP analyses with a good signal-to-noise ratio), eg, through time pressure, will be necessary.

In conclusion, our findings provide new evidence of altered neuronal activity during inhibition processes that are associated with heightened proneness to relapse, and highlight the fundamental usefulness of neuroimaging techniques to appropriately appraise underlying neural processes of a cognitive function.[@b80-ndt-10-1025] We suggest conducting more comprehensive studies in future to confirm that increased P3d amplitudes after detoxification are reliable biological indicators of relapse. Obviously, a crucial next step before our measures can be applied in a clinical setting will be to establish normal P3d values and move from links between group-level with treatment outcomes/relapse to individual-level prediction. Also, in real life, life events, environmental triggers, and motivational factors have an influence on inhibition fluctuation, and their interaction with inhibition capacities may contribute to substance use. Future research should include other factors that may interact with poor inhibitory control in order to be more ecological. Clinically, individuals identified as particularly at risk of relapse could be directed to postdetoxification treatments, with the aim of improving cognitive control through neuropsychological rehabilitation programs.[@b35-ndt-10-1025]
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![Go/no-go task.\
**Notes:** Participants were confronted with six blocks of 133 stimuli, divided in to 93 "go" trials (letter M), and 40 "no-go" trials (letter W). The letters were superimposed on two nonalcohol-related background pictures (NAC), two alcohol-related background pictures (AC), or a neutral black background (NC). Reproduced from Petit et al. Alcohol-Related Context Modulates Performance of Social Drinkers in a Visual Go/No-Go Task: A Preliminary Assessment of Event-Related Potentials. *PloS One*. 2012;7:e37466.[@b14-ndt-10-1025] Copyright © 2012 Petit et al.](ndt-10-1025Fig1){#f1-ndt-10-1025}

![Original go/no-go P3 waves in the patient and control groups and resulting P3d waves at the FC1, FC2, and Cz sites.\
**Notes:** Grand averages of the go/no-go P3 waves (left side of graphs in each electrode site) picturing the similar go P3 mean amplitude waves between groups (red and blue continuous lines) and the higher no-go P3 mean waves in patients (red dotted lines) in terms of amplitudes compared to controls (blue dotted lines), underlying the higher P3d amplitudes (ie, the mean difference wave = the go P3 wave subtracted from the no-go P3 wave) in patients compared to controls (red and blue continuous lines represented on the right of graphs in each electrode site).](ndt-10-1025Fig2){#f2-ndt-10-1025}

![(**A**) Grand averages of the P3-difference waveforms between go and no-go trials in control, relapser, and nonrelapser groups. Computation of the P3d, ie, the mean difference wave (go P3 wave subtracted from the no-go P3 wave) for control, relapser, and nonrelapser groups at the FC1, Cz, and FC2 sites. The red line represents the relapser group's mean wave, whose amplitude was greater than the nonrelapser (blue line) and control groups (green line). (**B**) Mean individual P3d amplitudes in patient group. Mean difference wave (go P3 wave subtracted from the no-go P3 wave) for each patient derived from the computation of the six electrode sites (FC1, FC2, Cz, CP1, CP2, and Pz) and the three contexts (nonalcohol-related background pictures \[NAC\], two alcohol-related background pictures \[AC\], neutral black background \[NC\]) collapsed as a function of their abstinence status at 3-month follow-up: relapsers are represented in red, and nonrelapsers are represented in blue.](ndt-10-1025Fig3){#f3-ndt-10-1025}

###### 

Clinical characteristics of patients and controls, presented as means ± standard deviation

                                                                 Patients (n=27)   Controls (n=27)   *P*-value
  -------------------------------------------------------------- ----------------- ----------------- -----------
  Females                                                        7                 7                 1.000
  Age (years)                                                    45 (12)           45 (11)           0.876
  Education level[\*](#tfn1-ndt-10-1025){ref-type="table-fn"}    12 (3)            16 (2)            \<0.001
  Body mass index                                                24 (4)            26 (4)            0.089
  Alcohol problems (AUDIT)                                       32 (7)            4 (2)             \<0.001
  Daily alcohol intake (U) (prior detoxification for patients)   23 (14)           0.5 (0.4)         \<0.001
  Smoking (% with nicotine dependence)                           85                13                \<0.001
  Depression (BDI score)                                         21 (12)           7 (9)             \<0.001
  Anxiety traits (STAI-B)                                        48 (9)            38 (9)            0.001
  Anxiety state (STAI-A)                                         49 (8)            40 (9)            0.001
  Impulsivity (UPPS scale)                                       109 (17)          95 (19)           0.006
  Degree of family history of alcoholism                         1.85 (1.3)        0.22 (0.8)        \<0.001

**Notes:**

Number of years of education since completing primary school; one unit (U) represents 10 g of alcohol.

**Abbreviations:** AUDIT, Alcohol Use Disorders Identification Test; BDI, Beck Depression Inventory; STAI, State-Trait Anxiety Inventory; UPPS, urgency (lack of), premeditation, perseverance (lack of), sensation seeking.

###### 

Reaction times (RTs) to "go" stimuli, error rates, go, no-go, and P3d amplitudes in patients and controls, presented as means ± standard deviation

                               Patients      Controls     *P*-value
  ---------------------------- ------------- ------------ ----------------------------------------------------
  Go RTs(ms)                   359 (56)      364 (58)     0.731
  Omission error rates (%)     1.6 (2.1)     0.5 (0.7)    0.003[\*](#tfn3-ndt-10-1025){ref-type="table-fn"}
  Commission error rates (%)   22.9 (12.4)   11.4 (6.6)   \<0.001[†](#tfn4-ndt-10-1025){ref-type="table-fn"}
  Go P3 (μV)                   9.5 (3.7)     9.6 (4.9)    0.877
  No-go P3 (μV)                13.9 (4.5)    12.6 (4.6)   0.026[‡](#tfn5-ndt-10-1025){ref-type="table-fn"}
  P3d (μV)                     4.4 (3.1)     2.9 (3.2)    0.034[‡](#tfn5-ndt-10-1025){ref-type="table-fn"}

**Notes:**

*P*\<0.005

*P*\<0.001

*P*\<0.05.

###### 

Clinical characteristics of relapsers and nonrelapsers in our study, presented as means ± standard deviation

                                                                              Relapsers (n=13)   Nonrelapsers (n=14)   *P*-value
  --------------------------------------------------------------------------- ------------------ --------------------- -----------
  Females                                                                     3                  4                     0.745
  Age (years)                                                                 39 (9)             50 (13)               0.018
  Education level[\*](#tfn6-ndt-10-1025){ref-type="table-fn"}                 11 (2)             12 (3)                0.645
  Body mass index                                                             25 (5)             22 (3)                0.123
  Alcohol problems (AUDIT)                                                    31 (4)             32 (9)                0.846
  Alcohol intake prior to detoxification (U/day)                              20 (12)            24 (16)               0.517
  Age of onset of alcohol misuse[†](#tfn7-ndt-10-1025){ref-type="table-fn"}   31 (11)            36 (11)               0.256
  Duration of current treatment (days)                                        18.6 (2.8)         19.4 (1.8)            0.380
  Duration of dependence[‡](#tfn8-ndt-10-1025){ref-type="table-fn"} (years)   8 (7)              15 (9)                0.055
  Number of prior detoxifications                                             0.6 (0.8)          3.2 (5.1)             0.086
  Smoking (% with nicotine dependence)[@b70-ndt-10-1025]                      84                 71                    0.673
  Depression (BDI score)                                                      20 (9)             21 (14)               0.824
  Anxiety trait (STAI-B)                                                      47 (7)             51 (9)                0.233
  Anxiety state (STAI-A)                                                      46 (9)             49 (10)               0.470
  Impulsivity (UPPS scale)                                                    116 (14)           103 (17)              0.075
  Craving before experiment                                                   14 (2)             5 (11)                0.075
  Craving after experiment                                                    19 (33)            6 (21)                0.106
  Global craving score                                                        21 (32)            6 (14)                0.110
  Degree of family history of alcoholism                                      1.4 (1.4)          2.2 (1.2)             0.163
  Anticraving medication (% receiving treatment)                              84                 64                    0.228
  Campral                                                                     76                 43                    0.120
  Baclofen                                                                    7                  7                     0.741
  Antabuse                                                                    0                  7                     0.277
  Campral + baclofen                                                          0                  7                     0.519
  Benzodiazepine (% of users)                                                 30                 42                    0.402

**Notes:**

Number of years of education since completing primary school

age at which drinking first began to have an effect on the subject's life of which he/she did not approve

number of years that the subject fulfilled dependence criteria before assessment.

**Abbreviations:** AUDIT, Alcohol Use Disorders Identification Test; BDI, Beck Depression Inventory; STAI, State-Trait Anxiety Inventory; U/Day, alcohol dose unit per day; UPPS, urgency (lack of), premeditation, perseverance (lack of), sensation seeking.

###### 

Reaction times (RTs) to "go" stimuli, error rates, and P3d amplitudes in nonrelapsers and relapsers, presented as means ± standard deviation

                               Relapsers     Nonrelapsers   *P*-value
  ---------------------------- ------------- -------------- ----------------------------------------------------
  Go RTs (ms)                  351 (42)      367 (68)       0.449
  Omission error rates (%)     1.6 (2.9)     1.6 (1.5)      0.965
  Commission error rates (%)   21.2 (12.2)   24.5 (12.8)    0.496
  P3d (μV)                     4.4 (3.1)     2.9 (3.2)      0.026[\*](#tfn10-ndt-10-1025){ref-type="table-fn"}

**Notes:**

*F*~1,23~=5.673, *P*=0.026; *η*^2^=0.198, observed power =0.626.

###### 

Multiple hierarchical regression analysis examining predictors of relapse after the 3-month follow-up period

  Variable                 *β*      SE      OR (95% CI)
  ------------------------ -------- ------- ----------------------
  **Step 1**                                
   UPPS scale              0.037    0.030   1.03 (0.979--1.101)
   Craving                 0.022    0.025   1.02 (0.973--1.074)
   Medication              −0.707   1.17    0.493 (0.049--4.960)
   Inhibition-error rate   −0.070   0.050   0.932 (0.844--1.029)
   FHA                     −0.462   0.372   0.630 (0.304--1.305)
  **Step 2**                                
   UPPS scale              0.061    0.038   1.06 (0.987--1.144)
   Craving                 0.016    0.031   1.01 (0.957--1.080)
   Medication              −1.98    1.51    0.137 (0.007--2.666)
   Inhibition-error rate   −0.050   0.047   0.951 (0.867--1.043)
   FHA                     −0.270   0.395   0.763 (0.352--1.656)
   P3d amplitude           0.483    0.252   1.62 (0.988--2.657)

**Notes:** *β* represents the slope of the regression line. After a binary logistic regression model with simultaneous entry of the FHA score, craving score, UPPS scale score, P3d amplitude, inhibition-error rate, and use of anticraving medication (taking medication versus not taking medication), which significantly predicted the OR of relapse, in order to examine the unique contribution of the P3d amplitude beyond and above other variables, hierarchical regression was conducted with FHA, craving, and UPPS scores, inhibition error rate, and use of anticraving medication, entered as predictors in the first step. These variables did not predict relapse (*χ*^2^=8.168, *df*=5, *P*=0.147, Nagelkerke *R*^2^=0.348). In a second step, we entered the P3d amplitude. The addition of the P3d amplitude significantly contributed to the prediction of relapse above and beyond other variables (*χ*^2^=13.558, *df*=6, *P*=0.035, Nagelkerke *R*^2^=0.527), meaning that 52% of the variance of the relapse outcome was explained by the model. The P3d amplitude was the only variable that independently and significantly predicted the odds of relapse, with an OR of 1.620 (95% CI 0.988--2.657), Wald =3.656, *P*=0.05.

**Abbreviations:** FHA, family history of alcoholism; UPPS, urgency (lack of), premeditation, perseverance (lack of), sensation seeking; OR, odds ratio; df, degrees of freedom; CI, confidence interval; SE, standard error.

###### 

Multivariate Cox regression analysis with stepwise backward selection examining time to relapse within the 3-month follow-up period

  Variables                         Significance (*P*-value)   *β*     SE      OR (95% CI)
  --------------------------------- -------------------------- ------- ------- ----------------------
  **Included in final model**                                                  
   UPPS scale                       0.04                       0.032   0.016   1.032 (1.001--1.065)
   P3d amplitude                    0.05                       0.199   0.104   1.220 (0.995--1.497)
  **Not included in final model**                                              
   Craving                          0.50                                       
   FHA                              0.12                                       
   Medication                       0.16                                       
   Inhibition-error rate            0.95                                       

**Notes:** *β* represents the slope of the regression line. The outcome variable assessed was the time to relapse within the 3-month follow-up window, and the unit of time for our analysis was 1 day. Participants remaining abstinent from alcohol by the end of the study window constituted the censored cases for this analysis. Initially, the six variables were included in the model. In a stepwise fashion, factors that showed no or limited statistically significant association with relapse adjusted for the remaining factors in the model were deleted. Two variables remained at the end: P3d amplitude and the UPPS scale score. Both variables constituted the best predictors of relapse, and they significantly and slightly significantly predicted the timing of relapse (UPPS, OR 1.032, 95% CI 1.001--1.065, *P*=0.04; P3d, OR 1.220, 95% CI 0.995--1.497, *P*=0.05).

**Abbreviations:** UPPS, urgency (lack of), premeditation, perseverance (lack of), sensation seeking; OR, odds ratio; CI, confidence interval; SE, standard error; FHA, family history of alcoholism.
